Last reviewed · How we verify

Henogen HBV vaccine

Henogen · Phase 3 active Biologic

Henogen HBV vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus antigens.

Henogen HBV vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus antigens. Used for Prevention of hepatitis B virus infection.

At a glance

Generic nameHenogen HBV vaccine
SponsorHenogen
Drug classVaccine
TargetHepatitis B surface antigen (HBsAg)
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

The vaccine contains hepatitis B surface antigen (HBsAg) that triggers both humoral and cell-mediated immune responses, enabling the body to recognize and neutralize hepatitis B virus upon exposure. This prevents infection and chronic hepatitis B disease development in vaccinated individuals.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: